Calcitonin

Generic Name: Calcitonin
Brand Name: IPACALCIN®
Dosage Form: Injection 50U/1ml
Pharmacological Category: Bone Modulating Drugs
Therapeutic Category: Hormonal Drugs
Pregnancy Category: Category C

Pharmacology

Calcitonin acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin-salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action. The actions of calcitonin on bone and its role in normal human bone physiology are still incompletely understood.

Pharmacokinetics:

Calcitonins are rapidly inactivated when given orally.After injection,calcitonins are quickly metabolised,primarily in the kidneys but also I blood and peripheral tissues.Bioavailability has been reported to be about 70%;plasma protein bindings is about 30 to 40%.The inactive metabolites and a small proportion of unchanged drug are excreted in the urine.The elimination half-life after injection of calcitonin(human) is stated to be 60 minutes and of calcitonin(salmon) about 70 to 90 minutes.
Calcitonins are also absorbed through the nasal and rectal mucosa.Although figured have varied widley,about 3% of an intranasal dose of calcitonin(salmon)is reported to be bioavailable compared with the same dose given by intramuscular injection,with peak plasma concentrations occurring after about 30 to 40 minutes compared with 15 to 25 minutes after the parenteral dose.Elimination half-life has been reported to be about 16 to 43 minutes.

Indications:

Paget's Disease
At the present time, effectiveness has been demonstrated principally in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion.
In these patients, the biochemical abnormalities were substantially improved (more than 30% reduction) in about 2/3 of patients studied, and bone pain was improved in a similar fraction. A small number of documented instances of reversal of neurologic deficits have occurred, including improvement in the basilar compression syndrome, and improvement of spinal cord and spinal nerve lesions. At present, there is too little experience to predict the likelihood of improvement of any given neurologic lesion. Hearing loss, the most common neurologic lesion of Paget's disease, is improved infrequently (4 of 29 patients studied audiometrically).

Patients with increased cardiac output due to extensive Paget's disease have had measured decreases in cardiac output while receiving calcitonin. The number of treated patients in this category is still too small to predict how likely such a result will be.
The large majority of patients with localized, especially monostotic disease do not develop symptoms and most patients with mild symptoms can be managed with analgesics. There is no evidence that the prophylactic use of calcitonin is beneficial in asymptomatic patients, although treatment may be considered in exceptional circumstances in which there is extensive involvement of the skull or spinal cord with the possibility of irreversible neurologic damage. In these instances, treatment would be based on the demonstrated effect of calcitonin on Pagetic bone, rather than on clinical studies in the patient population in question.

Hypercalcemia
Miacalcin Injection is indicated for early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. It may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents.

Postmenopausal Osteoporosis
Miacalcin Injection is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years postmenopause with low bone mass relative to healthy premenopausal females. Miacalcin Injection should be reserved for patients who refuse or cannot tolerate estrogens or in whom estrogens are contraindicated. Use of Miacalcin Injection is recommended in conjunction with adequate calcium and vitamin D intake to prevent the progressive loss of bone mass. No evidence currently exists to indicate whether or not Miacalcin Injection decreases the risk of vertebral crush fractures or spinal deformity.

Contraindications:

Clinical allergy to synthetic calcitonin-salmon.

Precautions:

Calcitonin-salmon solution should be stored in the refrigerator, not frozen. Patients should allow a new bottle of nasal spray to warm to room temperature. It may be kept at room temperature for two to four weeks. The nasal spray pump should be primed before using. Patients should push the plunger until a mist is observed. This usually occurs within several pushes. Before using, the patient should blow his or her nose. The patient should alternate nostrils with each dose. The head should be kept upright. The pump should be pressed toward the bottle one time. The patient should not inhale when spraying. The patient should then inhale through the nose and exhale through the mouth. The nosepiece should be wiped clean after each use. Patients giving themselves an injection should check that the contents are clear. Patients should not inject medication that is colored or grainy.
Calcitonin should be used cautiously when breast feeding, as it may decrease the amount of available milk. Its use during pregnancy has not been adequately studied. However, animal studies indicated a risk for low birth weight offspring.

Drug Interactions:

2 drugs (lithium and foscarnet)known to have a moderate interaction and 2 drugs (morphine and cimetidine)known to have minor interaction with calcitonin.

Side Effects:

• feeling light-headed, fainting; or
• muscle stiffness.

Less serious side effects may include:
• warmth, redness, itching, or tingly feeling under your skin;
• nausea, loss of appetite, stomach pain;
• vomiting;
• skin rash or itching;
• increased urination, especially at night;
• eye pain;
• swelling in your feet; or
• swelling or irritation of the skin where an injection was given.

Storage:

• Store between 2-8 C°
• Protect from light and freezing

Packing:

• Injection 50U/1ml: Box of 5Ampoules

stdClass Object ( [nid] => 262 [type] => product [language] => en [uid] => 1 [status] => 1 [created] => 1373629753 [changed] => 1392757142 [comment] => 0 [promote] => 0 [moderate] => 0 [sticky] => 0 [tnid] => 133 [translate] => 0 [vid] => 262 [revision_uid] => 1 [title] => Calcitonin [body] =>
Image: 
Brand Name: 

IPACALCIN®

Dosage Form: 

Injection 50U/1ml

Pharmacological Category: 

Bone Modulating Drugs

Therapeutic Category: 

Hormonal Drugs

Pregnancy Category: 

Category C

Calcitonin acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin-salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action. The actions of calcitonin on bone and its role in normal human bone physiology are still incompletely understood.

Pharmacokinetics: 

Calcitonins are rapidly inactivated when given orally.After injection,calcitonins are quickly metabolised,primarily in the kidneys but also I blood and peripheral tissues.Bioavailability has been reported to be about 70%;plasma protein bindings is about 30 to 40%.The inactive metabolites and a small proportion of unchanged drug are excreted in the urine.The elimination half-life after injection of calcitonin(human) is stated to be 60 minutes and of calcitonin(salmon) about 70 to 90 minutes.
Calcitonins are also absorbed through the nasal and rectal mucosa.Although figured have varied widley,about 3% of an intranasal dose of calcitonin(salmon)is reported to be bioavailable compared with the same dose given by intramuscular injection,with peak plasma concentrations occurring after about 30 to 40 minutes compared with 15 to 25 minutes after the parenteral dose.Elimination half-life has been reported to be about 16 to 43 minutes.

Indications: 

Paget's Disease
At the present time, effectiveness has been demonstrated principally in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion.
In these patients, the biochemical abnormalities were substantially improved (more than 30% reduction) in about 2/3 of patients studied, and bone pain was improved in a similar fraction. A small number of documented instances of reversal of neurologic deficits have occurred, including improvement in the basilar compression syndrome, and improvement of spinal cord and spinal nerve lesions. At present, there is too little experience to predict the likelihood of improvement of any given neurologic lesion. Hearing loss, the most common neurologic lesion of Paget's disease, is improved infrequently (4 of 29 patients studied audiometrically).

Patients with increased cardiac output due to extensive Paget's disease have had measured decreases in cardiac output while receiving calcitonin. The number of treated patients in this category is still too small to predict how likely such a result will be.
The large majority of patients with localized, especially monostotic disease do not develop symptoms and most patients with mild symptoms can be managed with analgesics. There is no evidence that the prophylactic use of calcitonin is beneficial in asymptomatic patients, although treatment may be considered in exceptional circumstances in which there is extensive involvement of the skull or spinal cord with the possibility of irreversible neurologic damage. In these instances, treatment would be based on the demonstrated effect of calcitonin on Pagetic bone, rather than on clinical studies in the patient population in question.

Hypercalcemia
Miacalcin Injection is indicated for early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. It may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents.

Postmenopausal Osteoporosis
Miacalcin Injection is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years postmenopause with low bone mass relative to healthy premenopausal females. Miacalcin Injection should be reserved for patients who refuse or cannot tolerate estrogens or in whom estrogens are contraindicated. Use of Miacalcin Injection is recommended in conjunction with adequate calcium and vitamin D intake to prevent the progressive loss of bone mass. No evidence currently exists to indicate whether or not Miacalcin Injection decreases the risk of vertebral crush fractures or spinal deformity.

Contraindications: 

Clinical allergy to synthetic calcitonin-salmon.

Precautions: 

Calcitonin-salmon solution should be stored in the refrigerator, not frozen. Patients should allow a new bottle of nasal spray to warm to room temperature. It may be kept at room temperature for two to four weeks. The nasal spray pump should be primed before using. Patients should push the plunger until a mist is observed. This usually occurs within several pushes. Before using, the patient should blow his or her nose. The patient should alternate nostrils with each dose. The head should be kept upright. The pump should be pressed toward the bottle one time. The patient should not inhale when spraying. The patient should then inhale through the nose and exhale through the mouth. The nosepiece should be wiped clean after each use. Patients giving themselves an injection should check that the contents are clear. Patients should not inject medication that is colored or grainy.
Calcitonin should be used cautiously when breast feeding, as it may decrease the amount of available milk. Its use during pregnancy has not been adequately studied. However, animal studies indicated a risk for low birth weight offspring.

Drug Interactions: 

2 drugs (lithium and foscarnet)known to have a moderate interaction and 2 drugs (morphine and cimetidine)known to have minor interaction with calcitonin.

Side Effects: 

• feeling light-headed, fainting; or
• muscle stiffness.

Less serious side effects may include:
• warmth, redness, itching, or tingly feeling under your skin;
• nausea, loss of appetite, stomach pain;
• vomiting;
• skin rash or itching;
• increased urination, especially at night;
• eye pain;
• swelling in your feet; or
• swelling or irritation of the skin where an injection was given.

Storage: 

• Store between 2-8 C°
• Protect from light and freezing

Packing: 

• Injection 50U/1ml: Box of 5Ampoules

[log] => [revision_timestamp] => 1392757142 [format] => 1 [name] => root [picture] => [data] => a:5:{s:29:"taxonomy_image_disable_images";i:0;s:20:"l10n_client_disabled";i:0;s:13:"form_build_id";s:48:"form-aTcSqa5gxC3qlJ6qWYJHsxgkPEq9KwPBBC-KEX1q3PQ";s:18:"admin_compact_mode";b:1;s:7:"contact";i:0;} [path] => product/calcitonin [field_one_image] => Array ( [0] => Array ( [fid] => 227 [uid] => 1 [filename] => calcitonin_s.jpg [filepath] => sites/default/files/images/calcitonin_s.jpg [filemime] => image/jpeg [filesize] => 63946 [status] => 1 [timestamp] => 1329496555 [list] => 1 [data] => Array ( [alt] => [title] => ) [i18nsync] => 1 [nid] => 262 [view] => ) ) [field_administration_and_dosage] => Array ( [0] => Array ( [value] => [format] => [safe] => [view] => ) ) [field_brand_name] => Array ( [0] => Array ( [value] => IPACALCIN® [format] => 1 [safe] =>

IPACALCIN®

[view] =>

IPACALCIN®

) ) [field_contraindications] => Array ( [0] => Array ( [value] => Clinical allergy to synthetic calcitonin-salmon. [format] => 1 [safe] =>

Clinical allergy to synthetic calcitonin-salmon.

[view] =>

Clinical allergy to synthetic calcitonin-salmon.

) ) [field_dosage_form] => Array ( [0] => Array ( [value] => Injection 50U/1ml [format] => 1 [safe] =>

Injection 50U/1ml

[view] =>

Injection 50U/1ml

) ) [field_drug_interactions] => Array ( [0] => Array ( [value] => 2 drugs (lithium and foscarnet)known to have a moderate interaction and 2 drugs (morphine and cimetidine)known to have minor interaction with calcitonin. [format] => 1 [safe] =>

2 drugs (lithium and foscarnet)known to have a moderate interaction and 2 drugs (morphine and cimetidine)known to have minor interaction with calcitonin.

[view] =>

2 drugs (lithium and foscarnet)known to have a moderate interaction and 2 drugs (morphine and cimetidine)known to have minor interaction with calcitonin.

) ) [field_indications] => Array ( [0] => Array ( [value] =>

Paget's Disease
At the present time, effectiveness has been demonstrated principally in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion.
In these patients, the biochemical abnormalities were substantially improved (more than 30% reduction) in about 2/3 of patients studied, and bone pain was improved in a similar fraction. A small number of documented instances of reversal of neurologic deficits have occurred, including improvement in the basilar compression syndrome, and improvement of spinal cord and spinal nerve lesions. At present, there is too little experience to predict the likelihood of improvement of any given neurologic lesion. Hearing loss, the most common neurologic lesion of Paget's disease, is improved infrequently (4 of 29 patients studied audiometrically).


Patients with increased cardiac output due to extensive Paget's disease have had measured decreases in cardiac output while receiving calcitonin. The number of treated patients in this category is still too small to predict how likely such a result will be.
The large majority of patients with localized, especially monostotic disease do not develop symptoms and most patients with mild symptoms can be managed with analgesics. There is no evidence that the prophylactic use of calcitonin is beneficial in asymptomatic patients, although treatment may be considered in exceptional circumstances in which there is extensive involvement of the skull or spinal cord with the possibility of irreversible neurologic damage. In these instances, treatment would be based on the demonstrated effect of calcitonin on Pagetic bone, rather than on clinical studies in the patient population in question.


Hypercalcemia
Miacalcin Injection is indicated for early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. It may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents.


Postmenopausal Osteoporosis
Miacalcin Injection is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years postmenopause with low bone mass relative to healthy premenopausal females. Miacalcin Injection should be reserved for patients who refuse or cannot tolerate estrogens or in whom estrogens are contraindicated. Use of Miacalcin Injection is recommended in conjunction with adequate calcium and vitamin D intake to prevent the progressive loss of bone mass. No evidence currently exists to indicate whether or not Miacalcin Injection decreases the risk of vertebral crush fractures or spinal deformity.

[format] => 1 [safe] =>

Paget's Disease
At the present time, effectiveness has been demonstrated principally in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion.
In these patients, the biochemical abnormalities were substantially improved (more than 30% reduction) in about 2/3 of patients studied, and bone pain was improved in a similar fraction. A small number of documented instances of reversal of neurologic deficits have occurred, including improvement in the basilar compression syndrome, and improvement of spinal cord and spinal nerve lesions. At present, there is too little experience to predict the likelihood of improvement of any given neurologic lesion. Hearing loss, the most common neurologic lesion of Paget's disease, is improved infrequently (4 of 29 patients studied audiometrically).

Patients with increased cardiac output due to extensive Paget's disease have had measured decreases in cardiac output while receiving calcitonin. The number of treated patients in this category is still too small to predict how likely such a result will be.
The large majority of patients with localized, especially monostotic disease do not develop symptoms and most patients with mild symptoms can be managed with analgesics. There is no evidence that the prophylactic use of calcitonin is beneficial in asymptomatic patients, although treatment may be considered in exceptional circumstances in which there is extensive involvement of the skull or spinal cord with the possibility of irreversible neurologic damage. In these instances, treatment would be based on the demonstrated effect of calcitonin on Pagetic bone, rather than on clinical studies in the patient population in question.

Hypercalcemia
Miacalcin Injection is indicated for early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. It may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents.

Postmenopausal Osteoporosis
Miacalcin Injection is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years postmenopause with low bone mass relative to healthy premenopausal females. Miacalcin Injection should be reserved for patients who refuse or cannot tolerate estrogens or in whom estrogens are contraindicated. Use of Miacalcin Injection is recommended in conjunction with adequate calcium and vitamin D intake to prevent the progressive loss of bone mass. No evidence currently exists to indicate whether or not Miacalcin Injection decreases the risk of vertebral crush fractures or spinal deformity.

[view] =>

Paget's Disease
At the present time, effectiveness has been demonstrated principally in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion.
In these patients, the biochemical abnormalities were substantially improved (more than 30% reduction) in about 2/3 of patients studied, and bone pain was improved in a similar fraction. A small number of documented instances of reversal of neurologic deficits have occurred, including improvement in the basilar compression syndrome, and improvement of spinal cord and spinal nerve lesions. At present, there is too little experience to predict the likelihood of improvement of any given neurologic lesion. Hearing loss, the most common neurologic lesion of Paget's disease, is improved infrequently (4 of 29 patients studied audiometrically).

Patients with increased cardiac output due to extensive Paget's disease have had measured decreases in cardiac output while receiving calcitonin. The number of treated patients in this category is still too small to predict how likely such a result will be.
The large majority of patients with localized, especially monostotic disease do not develop symptoms and most patients with mild symptoms can be managed with analgesics. There is no evidence that the prophylactic use of calcitonin is beneficial in asymptomatic patients, although treatment may be considered in exceptional circumstances in which there is extensive involvement of the skull or spinal cord with the possibility of irreversible neurologic damage. In these instances, treatment would be based on the demonstrated effect of calcitonin on Pagetic bone, rather than on clinical studies in the patient population in question.

Hypercalcemia
Miacalcin Injection is indicated for early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. It may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents.

Postmenopausal Osteoporosis
Miacalcin Injection is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years postmenopause with low bone mass relative to healthy premenopausal females. Miacalcin Injection should be reserved for patients who refuse or cannot tolerate estrogens or in whom estrogens are contraindicated. Use of Miacalcin Injection is recommended in conjunction with adequate calcium and vitamin D intake to prevent the progressive loss of bone mass. No evidence currently exists to indicate whether or not Miacalcin Injection decreases the risk of vertebral crush fractures or spinal deformity.

) ) [field_packing] => Array ( [0] => Array ( [value] => • Injection 50U/1ml: Box of 5Ampoules [format] => 1 [safe] =>

• Injection 50U/1ml: Box of 5Ampoules

[view] =>

• Injection 50U/1ml: Box of 5Ampoules

) ) [field_pdf] => Array ( [0] => Array ( [fid] => 228 [uid] => 1 [filename] => calcitonin.pdf [filepath] => sites/default/files/pdf/calcitonin.pdf [filemime] => application/pdf [filesize] => 1020721 [status] => 1 [timestamp] => 1329496711 [list] => 1 [data] => [i18nsync] => 1 [nid] => 262 [view] => ) ) [field_pharmacokinetics] => Array ( [0] => Array ( [value] => Calcitonins are rapidly inactivated when given orally.After injection,calcitonins are quickly metabolised,primarily in the kidneys but also I blood and peripheral tissues.Bioavailability has been reported to be about 70%;plasma protein bindings is about 30 to 40%.The inactive metabolites and a small proportion of unchanged drug are excreted in the urine.The elimination half-life after injection of calcitonin(human) is stated to be 60 minutes and of calcitonin(salmon) about 70 to 90 minutes. Calcitonins are also absorbed through the nasal and rectal mucosa.Although figured have varied widley,about 3% of an intranasal dose of calcitonin(salmon)is reported to be bioavailable compared with the same dose given by intramuscular injection,with peak plasma concentrations occurring after about 30 to 40 minutes compared with 15 to 25 minutes after the parenteral dose.Elimination half-life has been reported to be about 16 to 43 minutes. [format] => 1 [safe] =>

Calcitonins are rapidly inactivated when given orally.After injection,calcitonins are quickly metabolised,primarily in the kidneys but also I blood and peripheral tissues.Bioavailability has been reported to be about 70%;plasma protein bindings is about 30 to 40%.The inactive metabolites and a small proportion of unchanged drug are excreted in the urine.The elimination half-life after injection of calcitonin(human) is stated to be 60 minutes and of calcitonin(salmon) about 70 to 90 minutes.
Calcitonins are also absorbed through the nasal and rectal mucosa.Although figured have varied widley,about 3% of an intranasal dose of calcitonin(salmon)is reported to be bioavailable compared with the same dose given by intramuscular injection,with peak plasma concentrations occurring after about 30 to 40 minutes compared with 15 to 25 minutes after the parenteral dose.Elimination half-life has been reported to be about 16 to 43 minutes.

[view] =>

Calcitonins are rapidly inactivated when given orally.After injection,calcitonins are quickly metabolised,primarily in the kidneys but also I blood and peripheral tissues.Bioavailability has been reported to be about 70%;plasma protein bindings is about 30 to 40%.The inactive metabolites and a small proportion of unchanged drug are excreted in the urine.The elimination half-life after injection of calcitonin(human) is stated to be 60 minutes and of calcitonin(salmon) about 70 to 90 minutes.
Calcitonins are also absorbed through the nasal and rectal mucosa.Although figured have varied widley,about 3% of an intranasal dose of calcitonin(salmon)is reported to be bioavailable compared with the same dose given by intramuscular injection,with peak plasma concentrations occurring after about 30 to 40 minutes compared with 15 to 25 minutes after the parenteral dose.Elimination half-life has been reported to be about 16 to 43 minutes.

) ) [field_pharmacological_category] => Array ( [0] => Array ( [value] => Bone Modulating Drugs [format] => 1 [safe] =>

Bone Modulating Drugs

[view] =>

Bone Modulating Drugs

) ) [field_precautions] => Array ( [0] => Array ( [value] => Calcitonin-salmon solution should be stored in the refrigerator, not frozen. Patients should allow a new bottle of nasal spray to warm to room temperature. It may be kept at room temperature for two to four weeks. The nasal spray pump should be primed before using. Patients should push the plunger until a mist is observed. This usually occurs within several pushes. Before using, the patient should blow his or her nose. The patient should alternate nostrils with each dose. The head should be kept upright. The pump should be pressed toward the bottle one time. The patient should not inhale when spraying. The patient should then inhale through the nose and exhale through the mouth. The nosepiece should be wiped clean after each use. Patients giving themselves an injection should check that the contents are clear. Patients should not inject medication that is colored or grainy. Calcitonin should be used cautiously when breast feeding, as it may decrease the amount of available milk. Its use during pregnancy has not been adequately studied. However, animal studies indicated a risk for low birth weight offspring. [format] => 1 [safe] =>

Calcitonin-salmon solution should be stored in the refrigerator, not frozen. Patients should allow a new bottle of nasal spray to warm to room temperature. It may be kept at room temperature for two to four weeks. The nasal spray pump should be primed before using. Patients should push the plunger until a mist is observed. This usually occurs within several pushes. Before using, the patient should blow his or her nose. The patient should alternate nostrils with each dose. The head should be kept upright. The pump should be pressed toward the bottle one time. The patient should not inhale when spraying. The patient should then inhale through the nose and exhale through the mouth. The nosepiece should be wiped clean after each use. Patients giving themselves an injection should check that the contents are clear. Patients should not inject medication that is colored or grainy.
Calcitonin should be used cautiously when breast feeding, as it may decrease the amount of available milk. Its use during pregnancy has not been adequately studied. However, animal studies indicated a risk for low birth weight offspring.

[view] =>

Calcitonin-salmon solution should be stored in the refrigerator, not frozen. Patients should allow a new bottle of nasal spray to warm to room temperature. It may be kept at room temperature for two to four weeks. The nasal spray pump should be primed before using. Patients should push the plunger until a mist is observed. This usually occurs within several pushes. Before using, the patient should blow his or her nose. The patient should alternate nostrils with each dose. The head should be kept upright. The pump should be pressed toward the bottle one time. The patient should not inhale when spraying. The patient should then inhale through the nose and exhale through the mouth. The nosepiece should be wiped clean after each use. Patients giving themselves an injection should check that the contents are clear. Patients should not inject medication that is colored or grainy.
Calcitonin should be used cautiously when breast feeding, as it may decrease the amount of available milk. Its use during pregnancy has not been adequately studied. However, animal studies indicated a risk for low birth weight offspring.

) ) [field_pregnancy_category] => Array ( [0] => Array ( [value] => Category C [format] => 1 [safe] =>

Category C

[view] =>

Category C

) ) [field_references] => Array ( [0] => Array ( [value] => [format] => [safe] => [view] => ) ) [field_side_effects] => Array ( [0] => Array ( [value] => • feeling light-headed, fainting; or • muscle stiffness. Less serious side effects may include: • warmth, redness, itching, or tingly feeling under your skin; • nausea, loss of appetite, stomach pain; • vomiting; • skin rash or itching; • increased urination, especially at night; • eye pain; • swelling in your feet; or • swelling or irritation of the skin where an injection was given. [format] => 1 [safe] =>

• feeling light-headed, fainting; or
• muscle stiffness.

Less serious side effects may include:
• warmth, redness, itching, or tingly feeling under your skin;
• nausea, loss of appetite, stomach pain;
• vomiting;
• skin rash or itching;
• increased urination, especially at night;
• eye pain;
• swelling in your feet; or
• swelling or irritation of the skin where an injection was given.

[view] =>

• feeling light-headed, fainting; or
• muscle stiffness.

Less serious side effects may include:
• warmth, redness, itching, or tingly feeling under your skin;
• nausea, loss of appetite, stomach pain;
• vomiting;
• skin rash or itching;
• increased urination, especially at night;
• eye pain;
• swelling in your feet; or
• swelling or irritation of the skin where an injection was given.

) ) [field_storage] => Array ( [0] => Array ( [value] => • Store between 2-8 C° • Protect from light and freezing [format] => 1 [safe] =>

• Store between 2-8 C°
• Protect from light and freezing

[view] =>

• Store between 2-8 C°
• Protect from light and freezing

) ) [field_therapeutic_category] => Array ( [0] => Array ( [value] => Hormonal Drugs [format] => 1 [safe] =>

Hormonal Drugs

[view] =>

Hormonal Drugs

) ) [field_related_products] => Array ( [0] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [1] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [2] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) ) [taxonomy] => Array ( [5] => stdClass Object ( [tid] => 5 [vid] => 1 [name] => Hormonal Drugs [description] => [weight] => 3 [language] => [trid] => 0 [v_weight_unused] => 0 ) ) [build_mode] => 0 [readmore] => [content] => Array ( [field_one_image] => Array ( [#type_name] => product [#context] => full [#field_name] => field_one_image [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -3 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => image_plain [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_one_image [#weight] => 0 [#theme] => imagefield_formatter_image_plain [#item] => Array ( [fid] => 227 [uid] => 1 [filename] => calcitonin_s.jpg [filepath] => sites/default/files/images/calcitonin_s.jpg [filemime] => image/jpeg [filesize] => 63946 [status] => 1 [timestamp] => 1329496555 [list] => 1 [data] => Array ( [alt] => [title] => ) [i18nsync] => 1 [nid] => 262 [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] => ) [#title] => [#description] => [#children] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_one_image [#title] => Image [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] => [#printed] => 1 ) [#title] => [#description] => [#children] =>
Image: 
[#printed] => 1 ) [field_brand_name] => Array ( [#type_name] => product [#context] => full [#field_name] => field_brand_name [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -2 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_brand_name [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => IPACALCIN® [format] => 1 [safe] =>

IPACALCIN®

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

IPACALCIN®

) [#title] => [#description] => [#children] =>

IPACALCIN®

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_brand_name [#title] => Brand Name [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

IPACALCIN®

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Brand Name: 

IPACALCIN®

[#printed] => 1 ) [field_dosage_form] => Array ( [#type_name] => product [#context] => full [#field_name] => field_dosage_form [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -1 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_dosage_form [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Injection 50U/1ml [format] => 1 [safe] =>

Injection 50U/1ml

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Injection 50U/1ml

) [#title] => [#description] => [#children] =>

Injection 50U/1ml

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_dosage_form [#title] => Dosage Form [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Injection 50U/1ml

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Dosage Form: 

Injection 50U/1ml

[#printed] => 1 ) [#pre_render] => Array ( [0] => content_alter_extra_weights ) [field_pharmacological_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pharmacological_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 0 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pharmacological_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Bone Modulating Drugs [format] => 1 [safe] =>

Bone Modulating Drugs

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Bone Modulating Drugs

) [#title] => [#description] => [#children] =>

Bone Modulating Drugs

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pharmacological_category [#title] => Pharmacological Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Bone Modulating Drugs

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Pharmacological Category: 

Bone Modulating Drugs

[#printed] => 1 ) [#content_extra_fields] => Array ( [title] => Array ( [label] => Generic Name [description] => Node module form. [weight] => -5 ) [body_field] => Array ( [label] => Pharmacology [description] => Node module form. [weight] => 3 [view] => body ) [revision_information] => Array ( [label] => Revision information [description] => Node module form. [weight] => 18 ) [author] => Array ( [label] => Authoring information [description] => Node module form. [weight] => 19 ) [options] => Array ( [label] => Publishing options [description] => Node module form. [weight] => 20 ) [language] => Array ( [label] => Language [description] => Locale module form. [weight] => -4 ) [translation] => Array ( [label] => Translation settings [description] => Translation module form. [weight] => 21 ) [menu] => Array ( [label] => Menu settings [description] => Menu module form. [weight] => 17 ) [taxonomy] => Array ( [label] => Taxonomy [description] => Taxonomy module form. [weight] => -3 ) [path] => Array ( [label] => Path settings [description] => Path module form. [weight] => 16 ) [custom_breadcrumbs] => Array ( [label] => Custom Breadcrumbs [description] => Custom Breadcrumbs module form. [weight] => 30 ) ) [field_therapeutic_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_therapeutic_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 1 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_therapeutic_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Hormonal Drugs [format] => 1 [safe] =>

Hormonal Drugs

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Hormonal Drugs

) [#title] => [#description] => [#children] =>

Hormonal Drugs

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_therapeutic_category [#title] => Therapeutic Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Hormonal Drugs

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Therapeutic Category: 

Hormonal Drugs

[#printed] => 1 ) [field_pregnancy_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pregnancy_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 2 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pregnancy_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Category C [format] => 1 [safe] =>

Category C

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Category C

) [#title] => [#description] => [#children] =>

Category C

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pregnancy_category [#title] => Pregnancy Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Category C

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Pregnancy Category: 

Category C

[#printed] => 1 ) [body] => Array ( [#weight] => 3 [#value] =>

Calcitonin acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin-salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action. The actions of calcitonin on bone and its role in normal human bone physiology are still incompletely understood.

[#title] => [#description] => [#printed] => 1 ) [field_pharmacokinetics] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pharmacokinetics [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 4 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pharmacokinetics [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Calcitonins are rapidly inactivated when given orally.After injection,calcitonins are quickly metabolised,primarily in the kidneys but also I blood and peripheral tissues.Bioavailability has been reported to be about 70%;plasma protein bindings is about 30 to 40%.The inactive metabolites and a small proportion of unchanged drug are excreted in the urine.The elimination half-life after injection of calcitonin(human) is stated to be 60 minutes and of calcitonin(salmon) about 70 to 90 minutes. Calcitonins are also absorbed through the nasal and rectal mucosa.Although figured have varied widley,about 3% of an intranasal dose of calcitonin(salmon)is reported to be bioavailable compared with the same dose given by intramuscular injection,with peak plasma concentrations occurring after about 30 to 40 minutes compared with 15 to 25 minutes after the parenteral dose.Elimination half-life has been reported to be about 16 to 43 minutes. [format] => 1 [safe] =>

Calcitonins are rapidly inactivated when given orally.After injection,calcitonins are quickly metabolised,primarily in the kidneys but also I blood and peripheral tissues.Bioavailability has been reported to be about 70%;plasma protein bindings is about 30 to 40%.The inactive metabolites and a small proportion of unchanged drug are excreted in the urine.The elimination half-life after injection of calcitonin(human) is stated to be 60 minutes and of calcitonin(salmon) about 70 to 90 minutes.
Calcitonins are also absorbed through the nasal and rectal mucosa.Although figured have varied widley,about 3% of an intranasal dose of calcitonin(salmon)is reported to be bioavailable compared with the same dose given by intramuscular injection,with peak plasma concentrations occurring after about 30 to 40 minutes compared with 15 to 25 minutes after the parenteral dose.Elimination half-life has been reported to be about 16 to 43 minutes.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Calcitonins are rapidly inactivated when given orally.After injection,calcitonins are quickly metabolised,primarily in the kidneys but also I blood and peripheral tissues.Bioavailability has been reported to be about 70%;plasma protein bindings is about 30 to 40%.The inactive metabolites and a small proportion of unchanged drug are excreted in the urine.The elimination half-life after injection of calcitonin(human) is stated to be 60 minutes and of calcitonin(salmon) about 70 to 90 minutes.
Calcitonins are also absorbed through the nasal and rectal mucosa.Although figured have varied widley,about 3% of an intranasal dose of calcitonin(salmon)is reported to be bioavailable compared with the same dose given by intramuscular injection,with peak plasma concentrations occurring after about 30 to 40 minutes compared with 15 to 25 minutes after the parenteral dose.Elimination half-life has been reported to be about 16 to 43 minutes.

) [#title] => [#description] => [#children] =>

Calcitonins are rapidly inactivated when given orally.After injection,calcitonins are quickly metabolised,primarily in the kidneys but also I blood and peripheral tissues.Bioavailability has been reported to be about 70%;plasma protein bindings is about 30 to 40%.The inactive metabolites and a small proportion of unchanged drug are excreted in the urine.The elimination half-life after injection of calcitonin(human) is stated to be 60 minutes and of calcitonin(salmon) about 70 to 90 minutes.
Calcitonins are also absorbed through the nasal and rectal mucosa.Although figured have varied widley,about 3% of an intranasal dose of calcitonin(salmon)is reported to be bioavailable compared with the same dose given by intramuscular injection,with peak plasma concentrations occurring after about 30 to 40 minutes compared with 15 to 25 minutes after the parenteral dose.Elimination half-life has been reported to be about 16 to 43 minutes.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pharmacokinetics [#title] => Pharmacokinetics [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Calcitonins are rapidly inactivated when given orally.After injection,calcitonins are quickly metabolised,primarily in the kidneys but also I blood and peripheral tissues.Bioavailability has been reported to be about 70%;plasma protein bindings is about 30 to 40%.The inactive metabolites and a small proportion of unchanged drug are excreted in the urine.The elimination half-life after injection of calcitonin(human) is stated to be 60 minutes and of calcitonin(salmon) about 70 to 90 minutes.
Calcitonins are also absorbed through the nasal and rectal mucosa.Although figured have varied widley,about 3% of an intranasal dose of calcitonin(salmon)is reported to be bioavailable compared with the same dose given by intramuscular injection,with peak plasma concentrations occurring after about 30 to 40 minutes compared with 15 to 25 minutes after the parenteral dose.Elimination half-life has been reported to be about 16 to 43 minutes.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Pharmacokinetics: 

Calcitonins are rapidly inactivated when given orally.After injection,calcitonins are quickly metabolised,primarily in the kidneys but also I blood and peripheral tissues.Bioavailability has been reported to be about 70%;plasma protein bindings is about 30 to 40%.The inactive metabolites and a small proportion of unchanged drug are excreted in the urine.The elimination half-life after injection of calcitonin(human) is stated to be 60 minutes and of calcitonin(salmon) about 70 to 90 minutes.
Calcitonins are also absorbed through the nasal and rectal mucosa.Although figured have varied widley,about 3% of an intranasal dose of calcitonin(salmon)is reported to be bioavailable compared with the same dose given by intramuscular injection,with peak plasma concentrations occurring after about 30 to 40 minutes compared with 15 to 25 minutes after the parenteral dose.Elimination half-life has been reported to be about 16 to 43 minutes.

[#printed] => 1 ) [field_indications] => Array ( [#type_name] => product [#context] => full [#field_name] => field_indications [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 5 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_indications [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] =>

Paget's Disease
At the present time, effectiveness has been demonstrated principally in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion.
In these patients, the biochemical abnormalities were substantially improved (more than 30% reduction) in about 2/3 of patients studied, and bone pain was improved in a similar fraction. A small number of documented instances of reversal of neurologic deficits have occurred, including improvement in the basilar compression syndrome, and improvement of spinal cord and spinal nerve lesions. At present, there is too little experience to predict the likelihood of improvement of any given neurologic lesion. Hearing loss, the most common neurologic lesion of Paget's disease, is improved infrequently (4 of 29 patients studied audiometrically).


Patients with increased cardiac output due to extensive Paget's disease have had measured decreases in cardiac output while receiving calcitonin. The number of treated patients in this category is still too small to predict how likely such a result will be.
The large majority of patients with localized, especially monostotic disease do not develop symptoms and most patients with mild symptoms can be managed with analgesics. There is no evidence that the prophylactic use of calcitonin is beneficial in asymptomatic patients, although treatment may be considered in exceptional circumstances in which there is extensive involvement of the skull or spinal cord with the possibility of irreversible neurologic damage. In these instances, treatment would be based on the demonstrated effect of calcitonin on Pagetic bone, rather than on clinical studies in the patient population in question.


Hypercalcemia
Miacalcin Injection is indicated for early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. It may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents.


Postmenopausal Osteoporosis
Miacalcin Injection is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years postmenopause with low bone mass relative to healthy premenopausal females. Miacalcin Injection should be reserved for patients who refuse or cannot tolerate estrogens or in whom estrogens are contraindicated. Use of Miacalcin Injection is recommended in conjunction with adequate calcium and vitamin D intake to prevent the progressive loss of bone mass. No evidence currently exists to indicate whether or not Miacalcin Injection decreases the risk of vertebral crush fractures or spinal deformity.

[format] => 1 [safe] =>

Paget's Disease
At the present time, effectiveness has been demonstrated principally in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion.
In these patients, the biochemical abnormalities were substantially improved (more than 30% reduction) in about 2/3 of patients studied, and bone pain was improved in a similar fraction. A small number of documented instances of reversal of neurologic deficits have occurred, including improvement in the basilar compression syndrome, and improvement of spinal cord and spinal nerve lesions. At present, there is too little experience to predict the likelihood of improvement of any given neurologic lesion. Hearing loss, the most common neurologic lesion of Paget's disease, is improved infrequently (4 of 29 patients studied audiometrically).

Patients with increased cardiac output due to extensive Paget's disease have had measured decreases in cardiac output while receiving calcitonin. The number of treated patients in this category is still too small to predict how likely such a result will be.
The large majority of patients with localized, especially monostotic disease do not develop symptoms and most patients with mild symptoms can be managed with analgesics. There is no evidence that the prophylactic use of calcitonin is beneficial in asymptomatic patients, although treatment may be considered in exceptional circumstances in which there is extensive involvement of the skull or spinal cord with the possibility of irreversible neurologic damage. In these instances, treatment would be based on the demonstrated effect of calcitonin on Pagetic bone, rather than on clinical studies in the patient population in question.

Hypercalcemia
Miacalcin Injection is indicated for early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. It may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents.

Postmenopausal Osteoporosis
Miacalcin Injection is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years postmenopause with low bone mass relative to healthy premenopausal females. Miacalcin Injection should be reserved for patients who refuse or cannot tolerate estrogens or in whom estrogens are contraindicated. Use of Miacalcin Injection is recommended in conjunction with adequate calcium and vitamin D intake to prevent the progressive loss of bone mass. No evidence currently exists to indicate whether or not Miacalcin Injection decreases the risk of vertebral crush fractures or spinal deformity.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Paget's Disease
At the present time, effectiveness has been demonstrated principally in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion.
In these patients, the biochemical abnormalities were substantially improved (more than 30% reduction) in about 2/3 of patients studied, and bone pain was improved in a similar fraction. A small number of documented instances of reversal of neurologic deficits have occurred, including improvement in the basilar compression syndrome, and improvement of spinal cord and spinal nerve lesions. At present, there is too little experience to predict the likelihood of improvement of any given neurologic lesion. Hearing loss, the most common neurologic lesion of Paget's disease, is improved infrequently (4 of 29 patients studied audiometrically).

Patients with increased cardiac output due to extensive Paget's disease have had measured decreases in cardiac output while receiving calcitonin. The number of treated patients in this category is still too small to predict how likely such a result will be.
The large majority of patients with localized, especially monostotic disease do not develop symptoms and most patients with mild symptoms can be managed with analgesics. There is no evidence that the prophylactic use of calcitonin is beneficial in asymptomatic patients, although treatment may be considered in exceptional circumstances in which there is extensive involvement of the skull or spinal cord with the possibility of irreversible neurologic damage. In these instances, treatment would be based on the demonstrated effect of calcitonin on Pagetic bone, rather than on clinical studies in the patient population in question.

Hypercalcemia
Miacalcin Injection is indicated for early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. It may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents.

Postmenopausal Osteoporosis
Miacalcin Injection is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years postmenopause with low bone mass relative to healthy premenopausal females. Miacalcin Injection should be reserved for patients who refuse or cannot tolerate estrogens or in whom estrogens are contraindicated. Use of Miacalcin Injection is recommended in conjunction with adequate calcium and vitamin D intake to prevent the progressive loss of bone mass. No evidence currently exists to indicate whether or not Miacalcin Injection decreases the risk of vertebral crush fractures or spinal deformity.

) [#title] => [#description] => [#children] =>

Paget's Disease
At the present time, effectiveness has been demonstrated principally in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion.
In these patients, the biochemical abnormalities were substantially improved (more than 30% reduction) in about 2/3 of patients studied, and bone pain was improved in a similar fraction. A small number of documented instances of reversal of neurologic deficits have occurred, including improvement in the basilar compression syndrome, and improvement of spinal cord and spinal nerve lesions. At present, there is too little experience to predict the likelihood of improvement of any given neurologic lesion. Hearing loss, the most common neurologic lesion of Paget's disease, is improved infrequently (4 of 29 patients studied audiometrically).

Patients with increased cardiac output due to extensive Paget's disease have had measured decreases in cardiac output while receiving calcitonin. The number of treated patients in this category is still too small to predict how likely such a result will be.
The large majority of patients with localized, especially monostotic disease do not develop symptoms and most patients with mild symptoms can be managed with analgesics. There is no evidence that the prophylactic use of calcitonin is beneficial in asymptomatic patients, although treatment may be considered in exceptional circumstances in which there is extensive involvement of the skull or spinal cord with the possibility of irreversible neurologic damage. In these instances, treatment would be based on the demonstrated effect of calcitonin on Pagetic bone, rather than on clinical studies in the patient population in question.

Hypercalcemia
Miacalcin Injection is indicated for early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. It may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents.

Postmenopausal Osteoporosis
Miacalcin Injection is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years postmenopause with low bone mass relative to healthy premenopausal females. Miacalcin Injection should be reserved for patients who refuse or cannot tolerate estrogens or in whom estrogens are contraindicated. Use of Miacalcin Injection is recommended in conjunction with adequate calcium and vitamin D intake to prevent the progressive loss of bone mass. No evidence currently exists to indicate whether or not Miacalcin Injection decreases the risk of vertebral crush fractures or spinal deformity.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_indications [#title] => Indications [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Paget's Disease
At the present time, effectiveness has been demonstrated principally in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion.
In these patients, the biochemical abnormalities were substantially improved (more than 30% reduction) in about 2/3 of patients studied, and bone pain was improved in a similar fraction. A small number of documented instances of reversal of neurologic deficits have occurred, including improvement in the basilar compression syndrome, and improvement of spinal cord and spinal nerve lesions. At present, there is too little experience to predict the likelihood of improvement of any given neurologic lesion. Hearing loss, the most common neurologic lesion of Paget's disease, is improved infrequently (4 of 29 patients studied audiometrically).

Patients with increased cardiac output due to extensive Paget's disease have had measured decreases in cardiac output while receiving calcitonin. The number of treated patients in this category is still too small to predict how likely such a result will be.
The large majority of patients with localized, especially monostotic disease do not develop symptoms and most patients with mild symptoms can be managed with analgesics. There is no evidence that the prophylactic use of calcitonin is beneficial in asymptomatic patients, although treatment may be considered in exceptional circumstances in which there is extensive involvement of the skull or spinal cord with the possibility of irreversible neurologic damage. In these instances, treatment would be based on the demonstrated effect of calcitonin on Pagetic bone, rather than on clinical studies in the patient population in question.

Hypercalcemia
Miacalcin Injection is indicated for early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. It may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents.

Postmenopausal Osteoporosis
Miacalcin Injection is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years postmenopause with low bone mass relative to healthy premenopausal females. Miacalcin Injection should be reserved for patients who refuse or cannot tolerate estrogens or in whom estrogens are contraindicated. Use of Miacalcin Injection is recommended in conjunction with adequate calcium and vitamin D intake to prevent the progressive loss of bone mass. No evidence currently exists to indicate whether or not Miacalcin Injection decreases the risk of vertebral crush fractures or spinal deformity.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Indications: 

Paget's Disease
At the present time, effectiveness has been demonstrated principally in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion.
In these patients, the biochemical abnormalities were substantially improved (more than 30% reduction) in about 2/3 of patients studied, and bone pain was improved in a similar fraction. A small number of documented instances of reversal of neurologic deficits have occurred, including improvement in the basilar compression syndrome, and improvement of spinal cord and spinal nerve lesions. At present, there is too little experience to predict the likelihood of improvement of any given neurologic lesion. Hearing loss, the most common neurologic lesion of Paget's disease, is improved infrequently (4 of 29 patients studied audiometrically).

Patients with increased cardiac output due to extensive Paget's disease have had measured decreases in cardiac output while receiving calcitonin. The number of treated patients in this category is still too small to predict how likely such a result will be.
The large majority of patients with localized, especially monostotic disease do not develop symptoms and most patients with mild symptoms can be managed with analgesics. There is no evidence that the prophylactic use of calcitonin is beneficial in asymptomatic patients, although treatment may be considered in exceptional circumstances in which there is extensive involvement of the skull or spinal cord with the possibility of irreversible neurologic damage. In these instances, treatment would be based on the demonstrated effect of calcitonin on Pagetic bone, rather than on clinical studies in the patient population in question.

Hypercalcemia
Miacalcin Injection is indicated for early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. It may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents.

Postmenopausal Osteoporosis
Miacalcin Injection is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years postmenopause with low bone mass relative to healthy premenopausal females. Miacalcin Injection should be reserved for patients who refuse or cannot tolerate estrogens or in whom estrogens are contraindicated. Use of Miacalcin Injection is recommended in conjunction with adequate calcium and vitamin D intake to prevent the progressive loss of bone mass. No evidence currently exists to indicate whether or not Miacalcin Injection decreases the risk of vertebral crush fractures or spinal deformity.

[#printed] => 1 ) [field_administration_and_dosage] => Array ( [#type_name] => product [#context] => full [#field_name] => field_administration_and_dosage [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 6 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_administration_and_dosage [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => [format] => [safe] => [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_administration_and_dosage [#title] => Administration and Dosage [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [field_contraindications] => Array ( [#type_name] => product [#context] => full [#field_name] => field_contraindications [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 7 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_contraindications [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Clinical allergy to synthetic calcitonin-salmon. [format] => 1 [safe] =>

Clinical allergy to synthetic calcitonin-salmon.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Clinical allergy to synthetic calcitonin-salmon.

) [#title] => [#description] => [#children] =>

Clinical allergy to synthetic calcitonin-salmon.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_contraindications [#title] => Contraindications [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Clinical allergy to synthetic calcitonin-salmon.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Contraindications: 

Clinical allergy to synthetic calcitonin-salmon.

[#printed] => 1 ) [field_precautions] => Array ( [#type_name] => product [#context] => full [#field_name] => field_precautions [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 8 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_precautions [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Calcitonin-salmon solution should be stored in the refrigerator, not frozen. Patients should allow a new bottle of nasal spray to warm to room temperature. It may be kept at room temperature for two to four weeks. The nasal spray pump should be primed before using. Patients should push the plunger until a mist is observed. This usually occurs within several pushes. Before using, the patient should blow his or her nose. The patient should alternate nostrils with each dose. The head should be kept upright. The pump should be pressed toward the bottle one time. The patient should not inhale when spraying. The patient should then inhale through the nose and exhale through the mouth. The nosepiece should be wiped clean after each use. Patients giving themselves an injection should check that the contents are clear. Patients should not inject medication that is colored or grainy. Calcitonin should be used cautiously when breast feeding, as it may decrease the amount of available milk. Its use during pregnancy has not been adequately studied. However, animal studies indicated a risk for low birth weight offspring. [format] => 1 [safe] =>

Calcitonin-salmon solution should be stored in the refrigerator, not frozen. Patients should allow a new bottle of nasal spray to warm to room temperature. It may be kept at room temperature for two to four weeks. The nasal spray pump should be primed before using. Patients should push the plunger until a mist is observed. This usually occurs within several pushes. Before using, the patient should blow his or her nose. The patient should alternate nostrils with each dose. The head should be kept upright. The pump should be pressed toward the bottle one time. The patient should not inhale when spraying. The patient should then inhale through the nose and exhale through the mouth. The nosepiece should be wiped clean after each use. Patients giving themselves an injection should check that the contents are clear. Patients should not inject medication that is colored or grainy.
Calcitonin should be used cautiously when breast feeding, as it may decrease the amount of available milk. Its use during pregnancy has not been adequately studied. However, animal studies indicated a risk for low birth weight offspring.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Calcitonin-salmon solution should be stored in the refrigerator, not frozen. Patients should allow a new bottle of nasal spray to warm to room temperature. It may be kept at room temperature for two to four weeks. The nasal spray pump should be primed before using. Patients should push the plunger until a mist is observed. This usually occurs within several pushes. Before using, the patient should blow his or her nose. The patient should alternate nostrils with each dose. The head should be kept upright. The pump should be pressed toward the bottle one time. The patient should not inhale when spraying. The patient should then inhale through the nose and exhale through the mouth. The nosepiece should be wiped clean after each use. Patients giving themselves an injection should check that the contents are clear. Patients should not inject medication that is colored or grainy.
Calcitonin should be used cautiously when breast feeding, as it may decrease the amount of available milk. Its use during pregnancy has not been adequately studied. However, animal studies indicated a risk for low birth weight offspring.

) [#title] => [#description] => [#children] =>

Calcitonin-salmon solution should be stored in the refrigerator, not frozen. Patients should allow a new bottle of nasal spray to warm to room temperature. It may be kept at room temperature for two to four weeks. The nasal spray pump should be primed before using. Patients should push the plunger until a mist is observed. This usually occurs within several pushes. Before using, the patient should blow his or her nose. The patient should alternate nostrils with each dose. The head should be kept upright. The pump should be pressed toward the bottle one time. The patient should not inhale when spraying. The patient should then inhale through the nose and exhale through the mouth. The nosepiece should be wiped clean after each use. Patients giving themselves an injection should check that the contents are clear. Patients should not inject medication that is colored or grainy.
Calcitonin should be used cautiously when breast feeding, as it may decrease the amount of available milk. Its use during pregnancy has not been adequately studied. However, animal studies indicated a risk for low birth weight offspring.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_precautions [#title] => Precautions [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Calcitonin-salmon solution should be stored in the refrigerator, not frozen. Patients should allow a new bottle of nasal spray to warm to room temperature. It may be kept at room temperature for two to four weeks. The nasal spray pump should be primed before using. Patients should push the plunger until a mist is observed. This usually occurs within several pushes. Before using, the patient should blow his or her nose. The patient should alternate nostrils with each dose. The head should be kept upright. The pump should be pressed toward the bottle one time. The patient should not inhale when spraying. The patient should then inhale through the nose and exhale through the mouth. The nosepiece should be wiped clean after each use. Patients giving themselves an injection should check that the contents are clear. Patients should not inject medication that is colored or grainy.
Calcitonin should be used cautiously when breast feeding, as it may decrease the amount of available milk. Its use during pregnancy has not been adequately studied. However, animal studies indicated a risk for low birth weight offspring.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Precautions: 

Calcitonin-salmon solution should be stored in the refrigerator, not frozen. Patients should allow a new bottle of nasal spray to warm to room temperature. It may be kept at room temperature for two to four weeks. The nasal spray pump should be primed before using. Patients should push the plunger until a mist is observed. This usually occurs within several pushes. Before using, the patient should blow his or her nose. The patient should alternate nostrils with each dose. The head should be kept upright. The pump should be pressed toward the bottle one time. The patient should not inhale when spraying. The patient should then inhale through the nose and exhale through the mouth. The nosepiece should be wiped clean after each use. Patients giving themselves an injection should check that the contents are clear. Patients should not inject medication that is colored or grainy.
Calcitonin should be used cautiously when breast feeding, as it may decrease the amount of available milk. Its use during pregnancy has not been adequately studied. However, animal studies indicated a risk for low birth weight offspring.

[#printed] => 1 ) [field_drug_interactions] => Array ( [#type_name] => product [#context] => full [#field_name] => field_drug_interactions [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 9 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_drug_interactions [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => 2 drugs (lithium and foscarnet)known to have a moderate interaction and 2 drugs (morphine and cimetidine)known to have minor interaction with calcitonin. [format] => 1 [safe] =>

2 drugs (lithium and foscarnet)known to have a moderate interaction and 2 drugs (morphine and cimetidine)known to have minor interaction with calcitonin.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

2 drugs (lithium and foscarnet)known to have a moderate interaction and 2 drugs (morphine and cimetidine)known to have minor interaction with calcitonin.

) [#title] => [#description] => [#children] =>

2 drugs (lithium and foscarnet)known to have a moderate interaction and 2 drugs (morphine and cimetidine)known to have minor interaction with calcitonin.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_drug_interactions [#title] => Drug Interactions [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

2 drugs (lithium and foscarnet)known to have a moderate interaction and 2 drugs (morphine and cimetidine)known to have minor interaction with calcitonin.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Drug Interactions: 

2 drugs (lithium and foscarnet)known to have a moderate interaction and 2 drugs (morphine and cimetidine)known to have minor interaction with calcitonin.

[#printed] => 1 ) [field_side_effects] => Array ( [#type_name] => product [#context] => full [#field_name] => field_side_effects [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 10 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_side_effects [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • feeling light-headed, fainting; or • muscle stiffness. Less serious side effects may include: • warmth, redness, itching, or tingly feeling under your skin; • nausea, loss of appetite, stomach pain; • vomiting; • skin rash or itching; • increased urination, especially at night; • eye pain; • swelling in your feet; or • swelling or irritation of the skin where an injection was given. [format] => 1 [safe] =>

• feeling light-headed, fainting; or
• muscle stiffness.

Less serious side effects may include:
• warmth, redness, itching, or tingly feeling under your skin;
• nausea, loss of appetite, stomach pain;
• vomiting;
• skin rash or itching;
• increased urination, especially at night;
• eye pain;
• swelling in your feet; or
• swelling or irritation of the skin where an injection was given.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• feeling light-headed, fainting; or
• muscle stiffness.

Less serious side effects may include:
• warmth, redness, itching, or tingly feeling under your skin;
• nausea, loss of appetite, stomach pain;
• vomiting;
• skin rash or itching;
• increased urination, especially at night;
• eye pain;
• swelling in your feet; or
• swelling or irritation of the skin where an injection was given.

) [#title] => [#description] => [#children] =>

• feeling light-headed, fainting; or
• muscle stiffness.

Less serious side effects may include:
• warmth, redness, itching, or tingly feeling under your skin;
• nausea, loss of appetite, stomach pain;
• vomiting;
• skin rash or itching;
• increased urination, especially at night;
• eye pain;
• swelling in your feet; or
• swelling or irritation of the skin where an injection was given.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_side_effects [#title] => Side Effects [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• feeling light-headed, fainting; or
• muscle stiffness.

Less serious side effects may include:
• warmth, redness, itching, or tingly feeling under your skin;
• nausea, loss of appetite, stomach pain;
• vomiting;
• skin rash or itching;
• increased urination, especially at night;
• eye pain;
• swelling in your feet; or
• swelling or irritation of the skin where an injection was given.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Side Effects: 

• feeling light-headed, fainting; or
• muscle stiffness.

Less serious side effects may include:
• warmth, redness, itching, or tingly feeling under your skin;
• nausea, loss of appetite, stomach pain;
• vomiting;
• skin rash or itching;
• increased urination, especially at night;
• eye pain;
• swelling in your feet; or
• swelling or irritation of the skin where an injection was given.

[#printed] => 1 ) [field_storage] => Array ( [#type_name] => product [#context] => full [#field_name] => field_storage [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 11 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_storage [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Store between 2-8 C° • Protect from light and freezing [format] => 1 [safe] =>

• Store between 2-8 C°
• Protect from light and freezing

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Store between 2-8 C°
• Protect from light and freezing

) [#title] => [#description] => [#children] =>

• Store between 2-8 C°
• Protect from light and freezing

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_storage [#title] => Storage [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Store between 2-8 C°
• Protect from light and freezing

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Storage: 

• Store between 2-8 C°
• Protect from light and freezing

[#printed] => 1 ) [field_packing] => Array ( [#type_name] => product [#context] => full [#field_name] => field_packing [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 12 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_packing [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Injection 50U/1ml: Box of 5Ampoules [format] => 1 [safe] =>

• Injection 50U/1ml: Box of 5Ampoules

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Injection 50U/1ml: Box of 5Ampoules

) [#title] => [#description] => [#children] =>

• Injection 50U/1ml: Box of 5Ampoules

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_packing [#title] => Packing [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Injection 50U/1ml: Box of 5Ampoules

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Packing: 

• Injection 50U/1ml: Box of 5Ampoules

[#printed] => 1 ) [field_references] => Array ( [#type_name] => product [#context] => full [#field_name] => field_references [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 13 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_references [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => [format] => [safe] => [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_references [#title] => References [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [field_pdf] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pdf [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 14 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pdf [#weight] => 0 [#theme] => filefield_formatter_default [#item] => Array ( [fid] => 228 [uid] => 1 [filename] => calcitonin.pdf [filepath] => sites/default/files/pdf/calcitonin.pdf [filemime] => application/pdf [filesize] => 1020721 [status] => 1 [timestamp] => 1329496711 [list] => 1 [data] => [i18nsync] => 1 [nid] => 262 [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] => ) [#title] => [#description] => [#children] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pdf [#title] => PDF [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] => [#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [field_related_products] => Array ( [#type_name] => product [#context] => full [#field_name] => field_related_products [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 15 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 0 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [1] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 1 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 1 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [2] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 2 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 2 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_related_products [#title] => Related Products [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [#title] => [#description] => [#children] =>
Image: 
Brand Name: 

IPACALCIN®

Dosage Form: 

Injection 50U/1ml

Pharmacological Category: 

Bone Modulating Drugs

Therapeutic Category: 

Hormonal Drugs

Pregnancy Category: 

Category C

Calcitonin acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin-salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action. The actions of calcitonin on bone and its role in normal human bone physiology are still incompletely understood.

Pharmacokinetics: 

Calcitonins are rapidly inactivated when given orally.After injection,calcitonins are quickly metabolised,primarily in the kidneys but also I blood and peripheral tissues.Bioavailability has been reported to be about 70%;plasma protein bindings is about 30 to 40%.The inactive metabolites and a small proportion of unchanged drug are excreted in the urine.The elimination half-life after injection of calcitonin(human) is stated to be 60 minutes and of calcitonin(salmon) about 70 to 90 minutes.
Calcitonins are also absorbed through the nasal and rectal mucosa.Although figured have varied widley,about 3% of an intranasal dose of calcitonin(salmon)is reported to be bioavailable compared with the same dose given by intramuscular injection,with peak plasma concentrations occurring after about 30 to 40 minutes compared with 15 to 25 minutes after the parenteral dose.Elimination half-life has been reported to be about 16 to 43 minutes.

Indications: 

Paget's Disease
At the present time, effectiveness has been demonstrated principally in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion.
In these patients, the biochemical abnormalities were substantially improved (more than 30% reduction) in about 2/3 of patients studied, and bone pain was improved in a similar fraction. A small number of documented instances of reversal of neurologic deficits have occurred, including improvement in the basilar compression syndrome, and improvement of spinal cord and spinal nerve lesions. At present, there is too little experience to predict the likelihood of improvement of any given neurologic lesion. Hearing loss, the most common neurologic lesion of Paget's disease, is improved infrequently (4 of 29 patients studied audiometrically).

Patients with increased cardiac output due to extensive Paget's disease have had measured decreases in cardiac output while receiving calcitonin. The number of treated patients in this category is still too small to predict how likely such a result will be.
The large majority of patients with localized, especially monostotic disease do not develop symptoms and most patients with mild symptoms can be managed with analgesics. There is no evidence that the prophylactic use of calcitonin is beneficial in asymptomatic patients, although treatment may be considered in exceptional circumstances in which there is extensive involvement of the skull or spinal cord with the possibility of irreversible neurologic damage. In these instances, treatment would be based on the demonstrated effect of calcitonin on Pagetic bone, rather than on clinical studies in the patient population in question.

Hypercalcemia
Miacalcin Injection is indicated for early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. It may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents.

Postmenopausal Osteoporosis
Miacalcin Injection is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years postmenopause with low bone mass relative to healthy premenopausal females. Miacalcin Injection should be reserved for patients who refuse or cannot tolerate estrogens or in whom estrogens are contraindicated. Use of Miacalcin Injection is recommended in conjunction with adequate calcium and vitamin D intake to prevent the progressive loss of bone mass. No evidence currently exists to indicate whether or not Miacalcin Injection decreases the risk of vertebral crush fractures or spinal deformity.

Contraindications: 

Clinical allergy to synthetic calcitonin-salmon.

Precautions: 

Calcitonin-salmon solution should be stored in the refrigerator, not frozen. Patients should allow a new bottle of nasal spray to warm to room temperature. It may be kept at room temperature for two to four weeks. The nasal spray pump should be primed before using. Patients should push the plunger until a mist is observed. This usually occurs within several pushes. Before using, the patient should blow his or her nose. The patient should alternate nostrils with each dose. The head should be kept upright. The pump should be pressed toward the bottle one time. The patient should not inhale when spraying. The patient should then inhale through the nose and exhale through the mouth. The nosepiece should be wiped clean after each use. Patients giving themselves an injection should check that the contents are clear. Patients should not inject medication that is colored or grainy.
Calcitonin should be used cautiously when breast feeding, as it may decrease the amount of available milk. Its use during pregnancy has not been adequately studied. However, animal studies indicated a risk for low birth weight offspring.

Drug Interactions: 

2 drugs (lithium and foscarnet)known to have a moderate interaction and 2 drugs (morphine and cimetidine)known to have minor interaction with calcitonin.

Side Effects: 

• feeling light-headed, fainting; or
• muscle stiffness.

Less serious side effects may include:
• warmth, redness, itching, or tingly feeling under your skin;
• nausea, loss of appetite, stomach pain;
• vomiting;
• skin rash or itching;
• increased urination, especially at night;
• eye pain;
• swelling in your feet; or
• swelling or irritation of the skin where an injection was given.

Storage: 

• Store between 2-8 C°
• Protect from light and freezing

Packing: 

• Injection 50U/1ml: Box of 5Ampoules

[#printed] => 1 ) [links] => Array ( [node_translation_fa] => Array ( [title] => فارسی [href] => node/133 [language] => stdClass Object ( [language] => fa [name] => Persian [native] => فارسی [direction] => 1 [enabled] => 1 [plurals] => 0 [formula] => [domain] => [prefix] => fa [weight] => 3 [javascript] => ) [attributes] => Array ( [title] => کلسی تونین [class] => translation-link ) ) ) )
button

CONTACT US:

Head Office:
Address: No.1, Beastoon Ave., Dr. Fatemi Sq., Tehran1431663135 Iran
Tel: (+98 21)-889 65323
Fax: (+98 21)-889 57056
Factory:
Address: Caspian tamin Pharmaceutical Co., Entrance 1, Rasht Industrial Zone, Rasht, Guilan, Iran
Tel: (+98 131) 338-2511- 8
Fax: (+98 131) 338 – 2517